3

FORM 3 SUBMISSION

Company: Acumen Pharmaceuticals, Inc.
Filed: January 4, 2023
Period of Report: January 4, 2023
Accession Number: 0001209191-23-001428

View Document ↗ View on SEC.gov ↗